<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00800137</url>
  </required_header>
  <id_info>
    <org_study_id>UOHI-02</org_study_id>
    <nct_id>NCT00800137</nct_id>
  </id_info>
  <brief_title>Bridge or Continue Coumadin for Device Surgery Randomized Controlled Trial</brief_title>
  <acronym>BRUISECONTROL</acronym>
  <official_title>Bridge or Continue Coumadin for Device Surgery Randomized Controlled Trial (BRUISE CONTROL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Heart Institute Research Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ottawa Heart Institute Research Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many cardiac patients requiring device (defibrillator or pacemaker) related surgery are on
      chronic oral anticoagulation therapy (usually coumadin). The risk of blood clot formation
      related to stopping oral anti-coagulant therapy is currently managed by using bridging
      heparin therapy in patients with moderate to high risk of blood clot formation. There is a
      substantial risk of bleeding in the pocket where the device is situated (pocket
      hematoma)related to bridging therapy. The purpose of this study is to compare the current
      standard of care of bridging with heparin to an experimental strategy of continuing coumadin
      therapy in higher risk patients undergoing device surgery, with the hypothesis being that the
      continued oral anti-coagulation group will have a lower pocket hematoma rate as compared to
      the bridging with heparin group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients will be equally randomized (1:1) to the Conventional/control arm (bridging
      anti-coagulation)or to the Experimental arm (continued coumadin). In the Conventional arm
      there are 2 options. Patients with greater than 5 days pre-implant will discontinue oral
      anti-coagulant (coumadin) 5 days before the procedure,and start full therapeutic doses of
      subcutaneous low molecular weight heparin (LMWH)3 days before the procedure. Patients with
      less than 5 days to implant can be given Vitamin K at the investigator's discretion and start
      full therapeutic doses of either subcutaneous LMWH or IV unfractionated Heparin (choice is at
      investigator discretion) when the INR is below the therapeutic range for the patient (usually
      greater than or equal to 2; 2.5 for some valve patients) and surgery to proceed when INR is
      less than 1.6. Oral anti-coagulant (coumadin) will resume on the evening of the procedure.
      Full dose LMWH injections or full dose IV heparin will be started 24 hours after surgery.

      In the Experimental arm patients will continue on their oral anti-coagulant (coumadin). The
      INR on the day of surgery will be &lt; 3.0.

      ASA will be continued in all patients. Plavix will be continued in patients with drug-eluting
      stents.

      Patients will be monitored for the development of any hematoma or bleeding event during
      admission. There will be a unblinded team responsible for device implant and follow-up and a
      blinded team responsible to monitor any bleeding events or hematoma and determine if it meets
      the primary endpoint criteria for the study. The blinded team will have no knowledge of the
      treatment arm and will be involved only if the patient develops a hematoma or bleeding event.
      All hematomas and bleeding events will be followed until resolution.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    At time of pre-specified 2nd interim analysis
  </why_stopped>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinically significant hematoma (defined as hematoma requiring reoperation and/or transfusion and/or unplanned or prolonged hospitalization and/or interruption of LMWH or IV heparin or oral anti-coagulant.</measure>
    <time_frame>Device implant until first routine post-op visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Components of the primary outcome,composite of all other major peri-operative bleeding events and thrombo-embolic events.</measure>
    <time_frame>Device implant to first routine post-op visit</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">984</enrollment>
  <condition>Hematoma</condition>
  <arm_group>
    <arm_group_label>Bridging anti-coagulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low Molecular Weight Heparin or IV unfractionated Heparin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continued oral anti-coagulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Coumadin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>low molecular weight heparin or unfractionated heparin</intervention_name>
    <description>For elective patients with greater than 5 days pre-implant; discontinue oral anti-coagulation (coumadin) 5 days before the procedure. Full therapeutic doses of subcutaneous LMWH 3 days before the procedure.
Patients with less than 5 days to implant can be given vitamin K (up to 2 mg) at the investigator discretion and start full therapeutic doses of either subcutaneous LMWH or IV Unfractionated Heparin (choice is at investigator's discretion) when INR is below the upper limit of the prescribed therapeutic range for the patient (usually greater than or equal to 2; 2.5 for some valve patients) and surgery to proceed when INR is less than 1.6.
Last dose given in the morning(ie. &gt; 24 hours)of the day prior to the procedure.
Oral anti-coagulation (coumadin) will be resumed on the evening of the procedure.
Full dose LMWH or full dose IV heparin will be restarted 24 hours after surgery.</description>
    <arm_group_label>Bridging anti-coagulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin or coumadin</intervention_name>
    <description>Continue on oral anti-coagulant (coumadin). INR on the day of surgery will be &lt; 3.0</description>
    <arm_group_label>Continued oral anti-coagulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Any patient undergoing elective device surgery (i.e. de novo device implantation or
             pulse generator change or lead replacement or pocket revision)

          2. Patient at moderate or high risk of arterial thrombo-embolic events (ATE) or high risk
             of venous thrombo-embolic events (VTE) (defined as one or more of following):

               -  Prosthetic mitral valve replacement

               -  Caged ball or tilting disc aortic valve prosthesis

               -  Bileaflet aortic valve prosthesis and one or more of: AF (atrial
                  Fibrillation/Atrial Flutter), prior stroke or TIA, hypertension, diabetes, CHF
                  age &gt;75

               -  AFib/Flutter associated with rheumatic valvular heart disease

               -  Non-rheumatic AFib/Flutter and CHADS2 risk criteria SCORE &gt; 2

               -  Non-rheumatic AFib/Flutter and stroke or TIA (within 3 months)

               -  Persistent/permanent AFib/Flutter on day of acceptance for device surgery AND
                  plan for cardioversion or DFT testing at device implant

               -  Recent (within 3 months) VTE

               -  Severe thrombophilia (Protein C or S deficiency or anti-thrombin or
                  anti-phospholipid antibodies or multiple abnormalities)

          3. Willing to self-inject or have a relative or friend or nurse inject LMWH

        Exclusion Criteria:

          1. Unable ro unwilling to provide informed consent

          2. History of noncompliance of medical therapy

          3. Renal failure with Cr &gt; 180 umol/l

          4. Prior Heparin induced thrombocytopenia

          5. Active device infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Birnie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Heart Institute Research Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto de Cardiologia - Fundação Universitária de Cardiologia</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90620 - 000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mazankowski Alberta Heart Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Jubilee Hospital</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R 4R2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winnipeg Health Sciences Centre</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2H 2A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John Regional Hospital</name>
      <address>
        <city>Saint John</city>
        <state>New Brunswick</state>
        <zip>E2L 4L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QEII Health Sciences Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Science Center</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's General Hospital</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <zip>N2M 1B2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Center</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southlake Regional Health Centre</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 2P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rouge Valley Hospital</name>
      <address>
        <city>Scarborough</city>
        <state>Ontario</state>
        <zip>M1E 5E9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mike's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cité-de-la-Santé Hospital</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <zip>H7M 3L9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University Health Center</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de L'Université de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2W 1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Sacré-Coeur de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Laval</name>
      <address>
        <city>Québec</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sherbrooke University Hospital Centre CHUS</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2008</study_first_submitted>
  <study_first_submitted_qc>November 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2008</study_first_posted>
  <last_update_submitted>April 8, 2013</last_update_submitted>
  <last_update_submitted_qc>April 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ottawa Heart Institute Research Corporation</investigator_affiliation>
    <investigator_full_name>David Birnie</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>coumadin</keyword>
  <keyword>device surgery</keyword>
  <keyword>pocket hematoma</keyword>
  <keyword>Pocket hematoma and device surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

